GT Biopharma Inc（GTBP）财务数据GTBPGT Biopharma Inc

In the context of the broader market, GTBP competes directly with industry leaders such as KALA and MBRX. With a market capitalization of $13.61M, it holds a leading position in the sector. When comparing efficiency, GTBP's gross margin of N/A stands against KALA's N/A and MBRX's N/A. Such benchmarking helps identify whether GT Biopharma Inc is trading at a premium or discount relative to its financial performance.

GT Biopharma has reported substantial net losses, including a $28.4 million loss for FY2025 and a $2.8 million loss for Q2 2026, indicating ongoing financial struggles. The company's current ratio improved to 4.14 in Q1 2026, suggesting better short-term liquidity management.